Emerging insights into transforming growth factor β Smad signal in hepatic fibrogenesis

Gut

Volumn 56, Issue 2, 2007, Pages 284-292

  Inagaki, Y ^a   Okazaki, I ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; COLLAGEN TYPE 1; GAMMA INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOGENIC PROTEIN 1; SCATTER FACTOR; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

CELL TYPE; FIBROGENESIS; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; IMMUNITY; LIVER FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

BONE MORPHOGENETIC PROTEINS; COLLAGEN; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; INTERFERONS; LIVER CIRRHOSIS; MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846951514     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.088690     Document Type: Review

References (90)

1. Roberts AB, Lamb LC, Newton DL, et al. Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc Natl Acad Sci USA 1980;77:3494- 8.
2. Bissell DM, Roulot D, George J. Transforming growth factor-β and the liver. Hepatology 2001;34:859-67.
3. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets. J Cell Mol Med 2005;10:76-99.
4. Massague J, Seoane J, Wotton D. Smad transcription factors. Gene Dev 2005;19:2783-810.
5. Breitkopf K, Sawitza I, Westhoff JH, et al. Thrombospondin 1 acts as a strong promoter of transforming growth factor β effects via two distinct mechanisms in hepatic stellate cells. Gut 2005;54:673- 81.
6. Kondou H, Mushiake S, Etani Y, et al. A blocking peptide for transforming growth factor-β1 activation prevents hepatic fibrosis in vivo. J Hepatol 2003;39:742-8.
7. Okuno M, Akita K, Moriwaki H, et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-β. Gastroenterology 2001;120:1784- 800.
8. Nakao A, Afrakhte M, Moren A, et al. Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling. Nature 1997;389:631-5.
9. Ebisawa T, Fukuchi M, Murakami G, et al. Smurf1 interacts with transforming growth factor-β type I receptor through Smad7 and induce receptor degradation. J Biol Chem 2001;276:12477-80.
10. Inagaki Y, Nemoto T, Nakao A. Transcriptional activation of type I collagen gene during hepatic fibrogenesis. In: Okazaki I, Ninomiya Y, Friedman SL, Tanikawa K, eds. Extracellular matrix and the liver-approach to gene therapy. New York: Academic Press, 2003:233-48.
11. Inagaki Y, Truter S, Ramirez F. Transforming growth factor-β stimulates α2(I) collagen gene expression through a cis-acting element that contains an Sp1 binding site. J Biol Chem 1994;269:14828-34.
12. Greenwel P, Inagaki Y, Hu W, et al. Sp1 is required for the early response of α2(I) collagen to transforming factor-β1. J Biol Chem 1997;272:19738-45.
13. Chen S-J, Yuan W, Lo S, et al. Interaction of Smad3 with a proximal Smad-binding element of the human α2(I) procollagen gene promoter required for transcriptional activation by TGF-β. J Cell Physiol 2000;183:381-92.
14. Zhang W, Oul J, Inagaki Y, et al. Synergistic cooperation between Sp1 and Smad3/Smad4 mediates transforming growth factor β1 stimulation of α2(I)-collagen (COL1A2) transcription. J Biol Chem 2000;275:39237-45.
15. Ghosh AK, Yuan W, Mori Y, et al. Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-β involves functional cooperation with p300/CBP transcriptional coactivators. Oncogene 2000;19:3546-55.
16. Inagaki Y, Truter S, Greenwel P, et al. Regulation of the α2(I) collagen gene transcription in fat-storing cells derived from a cirrhotic liver. Hepatology 1995;22:573-9.
17. Inagaki Y, Nemoto T, Nakao A, et al. Interaction between GC box binding factors and Smad proteins modulates cell lineage-specific α2(I) collagen gene transcription. J Biol Chem 2001;276: 16573-9.
18. Liu C, Gaca MDA, Swenson ES, et al. Smad2 and Smad3 are differentially activated by TGF-β in quiescent and activated hepatic stellate cells: constitutive nuclear localization of Smads in activated cells is TGF-β independent. J Biol Chem 2003;278:11721-8.
19. Tahashi Y, Matsuzaki K, Date M, et al. Differential regulation of TGF-β signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology 2002;35:49-61.
20. Inagaki Y, Mamura M, Kanamaru Y, et al. Constitutive phosphorylation and nuclear localization of Smad3 are correlated with increased collagen gene transcription in activated hepatic stellate cells. J Cell Physiol 2001;187:117-23.
21. Garcia-Trevijano ER, Iraburu MJ, Fontana L, et al. Transforming growth factor β1 induces the expression of α1(I) procollagen mRNA by a hydrogen peroxide-C/EBPβ-dependent mechanism in rat hepatic stellate cells. Hepatology 1999;29:960-70.
22. Tsukada S, Westwick JK, Ikejima K, et al. SMAD and p38 MAPK signaling pathways independently regulate α1(I) collagen gene expression in unstimulated and transforming growth factor-β-stimulated hepatic stellate cells. J Biol Chem 2005;280:10055-64.
23. Inagaki Y, Truter S, Bou-Gharios G, et al. Activation of proα2(I) collagen promoter during hepatic fibrogenesis in transgenic mice. Biochem Biophys Res Commun 1998;250:606-11.
24. Nomura M, Li E. Smad2 role in mesoderm formation, left-right patterning and craniofacial development. Nature 1998;393:786-90.
25. Yang X, Letterio JJ, Lechleider RJ, et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. EMBO J 1999;18:1280-91.
26. Piek E, Jun Ju W, Heyer J, et al. Functional characterization of transforming growth factor β signaling in Smad2- and Smad3-deficient fibroblasts. J Biol Chem 2001;276:19945-53.
27. Schnabl B, Kweon YO, Frederick JP, et al. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 2001;34:89-100.
28. Uemura M, Swenson ES, Gaca MDA, et al. Smad2 and Smad3 play different roles in rat hepatic stellate cell function and α-smooth muscle actin organization. Mol Biol Cell 2005;16:4214-24.
29. Inman GJ, Nicolas FJ, Callahan JF, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002;62:65-74.
30. Kretzschmar M, Doody J, Massague J. Opposing BMP and EGF signalling pathways converge on the TGF-β family mediator Smad1. Nature 1997;389:618-22.
31. Kretzschmar M, Doody J, Timokhina I, et al. A mechanism of repression of TGFβ/Smad signaling by oncogenic Ras. Gene Dev 1999;13:804-16.
32. Hanafusa H, Ninomiya-Tsuji J, Masuyama N, et al. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-β-induced gene expression. J Biol Chem 1999;274:27161-7.
33. Abecassis I, Rogier E, Vazquez A, et al. Evidence for a role of MSK1 in transforming growth factor-β-mediated responses through p38α and Smad signaling pathways. J Biol Chem 2004;279: 30474-9.
34. Engel ME, McDonnell MA, Law BK, et al. Independent SMAD and JNK signaling in transforming growth factor-β-mediated transcription. J Biol Chem 1999;274:37413-20.
35. Furukawa F, Matsuzaki K, Mori S, et al. p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 2003;38:879-89.
36. Yoshida K, Matsuzaki K, Mori S, et al. Transforming growth factor-β and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/Smad3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am J Pathol 2005;166:1029-39.
37. 9 myoblasts. FEBS Lett 2002;513:282-8.
38. Hayashida T, Poncelet A-C, Hubchak SC, et al. TGF-β1 activates MAP kinase in human mesangial cells: a possible role in collagen expression. Kidney Int 1999:1710-20.
39. Reunanen N, Foschi M, Han J, et al. Activation of extracellular signal-regulated kinase 1/2 inhibits type I collagen expression by human skin fibroblasts. J Biol Chem 2000;275:34634-9.
40. Wang S, Hirschberg R. BMP7 antagonizes TGF-beta-dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol 2003;284:F1006-13.
41. Izumi N, Mizuguchi S, Inagaki Y, et al. BMP-7 opposes TGFβ1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. Am J Physiol Lung Cell Mol Physiol 2006;290:L120-6.
42. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003;9:964-8.
43. Zeisberg M, Kalluri R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med 2004;82:175-81.
44. Rockey DC. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol 2005;3:95-107.
45. Inagaki Y, Truter S, Tanaka S, et al. Overlapping pathways mediate the opposing actions of tumor necrosis factor-α and transforming growth factor-β on α2(I) collagen gene transcription. J Biol Chem 1995;270:3353-8.
46. Greenwel P, Tanaka S, Penkov D, et al. Tumor necrosis factor alpha inhibits type I collagen synthesis through repressive CCAAT/enhancer-binding proteins. Mol Cell Biol 2000;20:912-18.
47. Bitzer M, von Gersdorff G, Liang D, et al. A mechanism of suppression of TGF-β/SMAD signaling by NF-κB/RelA. Genes Dev 2000;14:187-97.
48. Verrecchia F, Pessah M, Atfi A, et al. Tumor necrosis factor-α inhibits transforming growth factor-β/Smad signaling in human dermal fibroblasts via AP-1 activation. J Biol Chem 2000;275:30226-31.
49. Rockey DC, Maher JJ, Jarnagin WR, et al. Inhibition of rat hepatic lipocyte activation in culture by interferon-γ. Hepatology 1992;16:776-84.
50. Mallat A, Preaux A-M, Blazejewski S, et al. Interferon alpha and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 1995;21:1003-10.
51. Czaja MJ, Weiner FR, Takahashi S, et al. γ-interferon treatment inhibits collagen deposition in murine Schistosomiasis. Hepatology 1989;10:795-800.
52. Baroni GS, D'Ambrosio L, Curto P, et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 1996;23:1189-99.
53. Higashi K, Kouba DJ, Song Y-J, et al. A proximal element within the human α2(I) collagen (COL1A2) promoter, distinct from the tumor necrosis factor-α response element, mediates transcriptional repression by interferon-γ. Matrix Biol 1998;16:447-56.
54. Higashi K, Inagaki Y, Suzuki N, et al. Y-box-binding protein YB-1 mediates transcriptional repression of human α2(I) collagen gene expression by interferon-γ. J Biol Chem 2003;278:5156- 62.
55. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-β/Smad signalling by the interferon-γ/STAT pathway. Nature 1999;397:710-13.
56. Ghosh AK, Yuan W, Mori Y, et al. Antagonistic regulation of type I collagen gene expression by interferon-γ and transforming growth factor-β. Integration at the level of p300/CBP transcriptional coactivators. J Biol Chem 2001;276:11041-8.
57. Higashi K, Inagaki Y, Fujimori K, et al. Interferon-γ interferes with transforming growth factor-β signaling through direct interaction of YB-1 with Smad3. J Biol Chem 2003;278:43470-9.
58. Dooley S, Said HM, Gressner AM, et al. Y-box protein-1 is the crucial mediator of antifibrotic interferon-γ effects. J Biol Chem 2006;281:1784-95.
59. Hiramatsu N, Hayashi N, Kasahara A, et al. Improvement of liver fibrosis in chronic hepatitis patients treated with natural interferon alpha. Hepatology 1995;22:135-42.
60. Suou T, Hosho K, Kishimoto Y, et al. Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alpha. Hepatology 1995;22:426-31.
61. Manabe N, Chevallier M, Chossegros P, et al. Interferon-α 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology 1993;18:1344-9.
62. Sobesky R, Mathurin P, Charlotte F, et al. Modeling the impact of interferon alpha treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 1999;116:378-86.
63. Inagaki Y, Nemoto T, Kushida M, et al. Interferon a down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology 2003;38:890-9.
64. Matsuda Y, Matsumoto K, Ichida T, et al. Hepatocyte growth factor suppresses the onset of liver cirrhosis and abrogates lethal hepatic dysfunction in rats. J Biochem 1995;118:643-9.
65. Yasuda H, Imai E, Shiota A, et al. Antifibrotic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats. Hepatology 1996;24:636-42.
66. Ueki T, Kaneda Y, Tsutsui H, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999;5:226-30.
67. Ozaki I, Zhao G, Mizuta T, et al. Hepatocyte growth factor induces collagenase (matrix metalloproteinase-1) via the transcription factor Ets-1 in human hepatic stellate cells. J Hepatol 2002;36:169-78.
68. Kim W-H, Matsumoto K, Bessho K, et al. Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am J Pathol 2005;166:1017-28.
69. Qi Z, Atsuchi N, Ooshima A, et al. Blockade of type β transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci USA 1999;96:2345-9.
70. Nakamura T, Sakata R, Ueno T, et al. Inhibition of transforming growth factor-β prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 2000;32:247-55.
71. George J, Roulot D, Koteliansky VE, et al. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor β type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA 1999;96:12719-24.
72. Ueno H, Sakamoto T, Nakamura T, et al. A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats. Hum Gene Ther 2000;11:33-42.
73. Dooley S, Hamzavi J, Breitkopf K, et al. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 2003;125:178-91.
74. Janoschek N, van de Leur E, Gressner AM, et al. Induction of cell death in activated hepatic stellate cells by targeted gene expression of the thymidine kinase/ganciclovir system. Biochem Biophys Res Commun 2004;316:1107-15.
75. Inagaki Y, Kushida M, Higashi K, et al. Cell type-specific intervention of TGF-β/Smad signaling suppresses collagen gene expression and hepatic fibrosis in mice. Gastroenterology 2005;129:259-68.
76. Beljaars L, Molema G, Weert B, et al. Albumin modified with mannose 6-phosphate: a potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology 1999;29:1486-93.
77. Beljaars L, Weert B, Geerts A, et al. The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue. Biochem Pnarmacol 2003;66:1307-17.
78. Friedman SL, Yamasaki G, Wong L. Modulation of transforming growth factor β receptors of rat lipocytes during the hepatic wound healing process. Enhanced binding and reduced gene expression accompany cellular activation in culture and in vivo. J Biol Chem 1994;269:10551-8.
79. Meurer SK, Tihaa L, Lahme B, et al. Identification of endoglin in rat hepatic stellate cells: new insights into transforming growth factor β receptor signaling. J Biol Chem 2005;280:3078-87.
80. Knittel T, Kobold D, Saile B, et al. Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 1999;117:1205-21.
81. Magness ST, Bataller R, Yang L, et al. A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology 2004;40:1151-9.
82. Wells RG, Kruglov E, Dranoff JA. Autocrine release of TGF-β by portal fibroblasts regulates cell growth. FEBS Lett 2004;559:107-10.
83. S6k. Am J Physiol Gastrointest Liver Physiol 2004;287:G974-87.
84. Shaefer B, Rivas-Estilla AM, Meraz-Cruz N, et al. Reciprocal modulation of matrix metalloprofeinase-13 and type I collagen genes in rat hepatic stellate cells. Am J Pathol 2003;162:1771-80.
85. Terai S, Sakaida I, Yamamoto N, et al. An in vivo model for monitoring transdifferentiation of bone marrow cells into functional hepatocytes. J Biochem (Tokyo) 2003;134:551-8.
86. Sakaida I, Terai S, Yamamoto N, et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 2004;40:1304-11.
87. Forbes SJ, Russo FP, Rey V, et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 2004;126:955-63.
88. Russo FP, Alison MR, Bigger BW, et al. The bone marrow functionally contribute to liver fibrosis. Gastroenterology 2006;130:1807-21.
89. Lowes KN, Croager EJ, Olynyk JK, et al. Oval cell-mediated liver regeneration: role of cytokines and growth factors. J Gastroenterol Hepatol 2003;18:4-12.
90. Mishra L, Derynck R, Mishra B. Transforming growth factor-β signaling in stem cells and cancer. Science 2005;310:68-71.